All
  • All
  • ELISA Kit
  • Protein
  • Antibody
  • Molecular Biology Product
  • Small Molecule
  • Peptide
All
  • All
  • ELISA Kit
  • Protein
  • Antibody
  • Molecular Biology Product
  • Small Molecule
  • Peptide

Recombinant Human Hepatocyte growth factor receptor (MET), partial (Active)

In Stock
Code CSB-MP013714HU
MSDS
MSDS Datasheet
Size $102
Order now
Image
  • CSB-MP013714HU-SDS
    (Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.
  • CSB-MP013714HU-AC1
    Activity
    Measured by its binding ability in a functional ELISA. Immobilized MET at 2 μg/ml can bind Anti-MET recombinant antibody, the EC50 is 2.379-3.094 ng/ml. Biological Activity Assay
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Purity
Greater than 90% as determined by SDS-PAGE.
Endotoxin
Less than 1.0 EU/ug as determined by LAL method.
Activity
①Measured by its binding ability in a functional ELISA. Immobilized MET at 2 μg/ml can bind Anti-MET recombinant antibody, the EC50 is 2.379-3.094 ng/ml.
Target Names
MET
Uniprot No.
P08581
Research Area
Cancer
Alternative Names
(HGF receptor)(HGF/SF receptor)(Proto-oncogene c-Met)(Scatter factor receptor)(SF receptor)(Tyrosine-protein kinase Met)
Molecular Characterization
Species
Homo sapiens (Human)
Source
Mammalian cell
Expression Region
25-932aa
Target Protein Sequence
ECKEALAKSEMNVNMKYQLPNFTAETPIQNVILHEHHIFLGATNYIYVLNEEDLQKVAEYKTGPVLEHPDCFPCQDCSSKANLSGGVWKDNINMALVVDTYYDDQLISCGSVNRGTCQRHVFPHNHTADIQSEVHCIFSPQIEEPSQCPDCVVSALGAKVLSSVKDRFINFFVGNTINSSYFPDHPLHSISVRRLKETKDGFMFLTDQSYIDVLPEFRDSYPIKYVHAFESNNFIYFLTVQRETLDAQTFHTRIIRFCSINSGLHSYMEMPLECILTEKRKKRSTKKEVFNILQAAYVSKPGAQLARQIGASLNDDILFGVFAQSKPDSAEPMDRSAMCAFPIKYVNDFFNKIVNKNNVRCLQHFYGPNHEHCFNRTLLRNSSGCEARRDEYRTEFTTALQRVDLFMGQFSEVLLTSISTFIKGDLTIANLGTSEGRFMQVVVSRSGPSTPHVNFLLDSHPVSPEVIVEHTLNQNGYTLVITGKKITKIPLNGLGCRHFQSCSQCLSAPPFVQCGWCHDKCVRSEECLSGTWTQQICLPAIYKVFPNSAPLEGGTRLTICGWDFGFRRNNKFDLKKTRVLLGNESCTLTLSESTMNTLKCTVGPAMNKHFNMSIIISNGHGTTQYSTFSYVDPVITSISPKYGPMAGGTLLTLTGNYLNSGNSRHISIGGKTCTLKSVSNSILECYTPAQTISTEFAVKLKIDLANRETSIFSYREDPIVYEIHPTKSFISGGSTITGVGKNLNSVSVPRMVINVHEAGRNFTVACQHRSNSEIICCTTPSLQQLNLQLPLKTKAFFMLDGILSKYFDLIYVHNPVFKPFEKPVMISMGNENVLEIKGNDIDPEAVKGEVLKVGNKSCENIHLHSEAVLCTVPNDLLKLNSELNIEWKQAISSTVLGKVIVQPDQNFT
Mol. Weight
130.6 kDa
Protein Length
Partial
Tag Info
C-terminal hFc1-tagged
Form
Lyophilized powder
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
Buffer
Lyophilized from a 0.2 μm filtered PBS, 6% Trehalose, pH 7.4
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. Our default final concentration of glycerol is 50%. Customers could use it as reference.
Troubleshooting and FAQs
Protein FAQs
Storage Condition
Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
Shelf Life
The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
Lead Time
3-7 business days
Notes
Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Datasheet & COA
Please contact us to get it.
Description

The recombinant human MET is a high-purity protein with endotoxin levels below 1.0 EU/μg, as determined by the LAL method. Its purity is over 90% as measured by SDS-PAGE. It is expressed with the plasmid that contains the gene fragment encoding the 25-932aa of human MET and the C-terminal hFc-tag gene in mammalian cells. The recombinant MET protein's activity has been validated via functional ELISA, showing a binding EC50 of 2.379-3.094 ng/ml with an anti-MET recombinant antibody.

The human HGFR, also called c-Met/MET, is a receptor tyrosine kinase that plays a critical role in various physiological processes, including cell growth, motility, and differentiation. Upon binding of HGF, c-Met undergoes dimerization, which activates its intrinsic tyrosine kinase activity, leading to autophosphorylation and the recruitment of downstream signaling molecules [1][2]. This activation cascade is essential for mediating various cellular responses, including DNA synthesis, cell migration, and tissue regeneration [3][4].

The HGF/c-Met signaling pathway is also important for pathological conditions, particularly in cancer progression and metastasis. Aberrant activation of the c-Met pathway has been implicated in several malignancies, contributing to tumor growth, invasion, and metastasis [5-7]. Additionally, mutations in the MET gene have been associated with various diseases, including nonsyndromic hearing loss, underscoring the receptor's diverse biological roles [8].

References:
[1] C. Basilico, A. Arnesano, M. Galluzzo, P. Comoglio, & P. Michieli, A high-affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of met, Journal of Biological Chemistry, vol. 283, no. 30, p. 21267-21277, 2008. https://doi.org/10.1074/jbc.m800727200
[2] J. Rubin, R. Day, D. Breckenridge, N. Atabey, W. Taylor, S. Stahlet al., Dissociation of heparan sulfate and receptor binding domains of hepatocyte growth factor reveals that heparan sulfate-c-met interaction facilitates signaling, Journal of Biological Chemistry, vol. 276, no. 35, p. 32977-32983, 2001. https://doi.org/10.1074/jbc.m105486200
[3] S. Paranjpe, W. Bowen, A. Bell, K. Nejak‐Bowen, J. Luo, & G. Michalopoulos, Cell cycle effects resulting from inhibition of hepatocyte growth factor and its receptor c-met in regenerating rat livers by rna interference, Hepatology, vol. 45, no. 6, p. 1471-1477, 2007. https://doi.org/10.1002/hep.21570
[4] T. Kato, Biological roles of hepatocyte growth factor‑met signaling from genetically modified animals (review), Biomedical Reports, 2017. https://doi.org/10.3892/br.2017.1001
[5] S. Aguirre, J. Heyen, W. Collette, W. Bobrowski, & E. Blasi, Cardiovascular effects in rats following exposure to a receptor tyrosine kinase inhibitor, Toxicologic Pathology, vol. 38, no. 3, p. 416-428, 2010. https://doi.org/10.1177/0192623310364027
[6] T. Takayanagi, Y. Aoki, & K. Tanaka, Expression of constitutively active c-met receptor in human choriocarcinoma, Gynecologic and Obstetric Investigation, vol. 50, no. 3, p. 198-202, 2000. https://doi.org/10.1159/000010310
[7] F. Shojaei, J. Lee, B. Simmons, A. Wong, C. Esparza, P. Plumleeet al., Hgf/c-met acts as an alternative angiogenic pathway in sunitinib-resistant tumors, Cancer Research, vol. 70, no. 24, p. 10090-10100, 2010. https://doi.org/10.1158/0008-5472.can-10-0489
[8] G. Mujtaba, J. Schultz, A. Imtiaz, R. Morell, T. Friedman, & S. Naz, A mutation ofmet, encoding hepatocyte growth factor receptor, is associated with humandfnb97hearing loss, Journal of Medical Genetics, vol. 52, no. 8, p. 548-552, 2015. https://doi.org/10.1136/jmedgenet-2015-103023

Related Products

MET Antibodies

MET Proteins

MET ELISA kits

Customer Reviews and Q&A

■ Customer Reviews
Average Rating:
5.0 - 1 reviews

Submit a Review here

Applications : ELISA standard and its raw materials

Review: I used the product CSB-MP013714HU to perform an ELISA experiment with the anti-MET antibody, and the EC50 was 0.8123-1.572 ng/ml, indicating good binding activity. In the subsequent screening of antibodies as standards, coated with a small amount of antigen, it could effectively bind, saving time and effort!

By Anonymous

Read more reviews >>

Target Background

Function
Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand. Regulates many physiological processes including proliferation, scattering, morphogenesis and survival. Ligand binding at the cell surface induces autophosphorylation of MET on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or the adapter GAB1. Recruitment of these downstream effectors by MET leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. The RAS-ERK activation is associated with the morphogenetic effects while PI3K/AKT coordinates prosurvival effects. During embryonic development, MET signaling plays a role in gastrulation, development and migration of muscles and neuronal precursors, angiogenesis and kidney formation. In adults, participates in wound healing as well as organ regeneration and tissue remodeling. Promotes also differentiation and proliferation of hematopoietic cells. May regulate cortical bone osteogenesis.; (Microbial infection) Acts as a receptor for Listeria monocytogenes internalin InlB, mediating entry of the pathogen into cells.
Gene References into Functions
  1. the miR-19a/c-Met pathway plays a critical role in acquired resistance to gefitinib and that the manipulation of miR-19a might provide a therapeutic strategy for overcoming acquired gefitinib resistance. PMID: 28592790
  2. The expression of C-Met and HER2 protein in lung adenocarcinoma is highly correlated, and whether it is synergistic in the targeted therapy of lung adenocarcinoma deserves further study. PMID: 29400000
  3. MET overexpression was more frequently found in high grade myxofibrosarcoma and the epithelioid variant. Chromosome 7 polysomy, rather than MET gene regional amplification, might account for the overexpression. of MET protein. PMID: 30126419
  4. miR-449a suppresses hepatocellular carcinoma tumorigenesis by down-regulating activity in the c-Met/ERK pathway. PMID: 30108016
  5. We found MET amplifications in two cases of endometrial clear-cell carcinoma with mixed features. PMID: 29633423
  6. Regarding gene mutation abundance, NGS enables the detection of low-abundant ctDNA in blood based on ultra-deep sequencing, and our patient benefited from crizotinib despite the low abundance of MET exon 14 skipping. These data indicate that we can choose targeted therapy despite the low abundance of gene mutations. PMID: 29110851
  7. The interplay of dual MET/HER2 overexpression in the AKT and ERK pathways for esophageal cancer is described. Therefore, combination therapy could be a novel strategy for EAC with amplification of both MET and HER2. PMID: 29223420
  8. MET inactivation in the context of the BRAF-activating mutation is driven through a negative feedback loop involving inactivation of PP2A phosphatase, which in turn leads to phosphorylation on MET inhibitory Ser985. PMID: 30224486
  9. MET Exon 14 Skipping Mutations in Non-small Cell Lung Cancer PMID: 30037377
  10. MET activation, by either METex14 mutations or amplification, is characteristic of a subset of early stage NSCLCs and may coexist with ERBB2 amplification. PMID: 29139039
  11. Results demonstrate that serum level of miR-658 is significantly lower in the NM group than in the DM group. Meanwhile, the levels of PAX3 and MET are lower in the NM group than in the DM group too. Both overexpression and silence of miR-658 significantly up-regulate or down-regulate the levels of PAX3 and MET in gastric cell lines. PMID: 29630524
  12. MiR-206 inhibits the development of epithelial ovarian cancer cell by directly targeting c-Met and inhibiting the c-Met/AKT/mTOR signaling pathway. PMID: 29807226
  13. These results suggest that gastric cancer progression is not associated with a unique signaling pathway and that a feedback loop may exist between the HGF/c-Met and Notch1 signaling pathways, which may result in therapeutic resistance. PMID: 29781036
  14. Comparative analysis revealed a strong association between MET expression and MET amplification (85% concurrence) in primary stomach tumors and matched liver metastasis. Survival analyses revealed that both MET amplification and MET overexpression were prognostic of poor outcomes. PMID: 29790169
  15. High c-met expression is associated with oral squamous cell carcinoma. PMID: 29286169
  16. FOXO1 serves as an important linker between HER2 and MET signaling pathways through negative crosstalks and is a key regulator of the acquired lapatinib resistance in HER2-positive GC cells. PMID: 28343375
  17. analysis of how the cMET blockade augments radiation therapy in patients with NF2 PMID: 29440379
  18. these findings highlight the relevance of cross-species protein interactions between murine feeder cells and human epithelial cells in 3T3-J2 co-culture and demonstrate that STAT6 phosphorylation occurs in response to MET activation in epithelial cells. However, STAT6 nuclear translocation does not occur in response to HGF, precluding the transcriptional activity of STAT6. PMID: 29771943
  19. c-Met-activated Mesenchymal Stem Cells (MSC) pre-exposed to hypoxia interact with PrPC at the site of ischemic injury to increase the efficiency of MSC transplantation. PMID: 29705776
  20. A novel G-quadruplex motif formed in the Human MET promoter region. PMID: 29054971
  21. a METex14 del mutation-positive NSCLC patient who responded to crizotinib but later relapsed, demonstrated a mixed response to glesatinib including reduction in size of a MET Y1230H mutation-positive liver metastasis and concurrent loss of detection of this mutation in plasma DNA. Together, these data demonstrate that glesatinib exhibits a distinct mechanism of target inhibition and can overcome resistance to PMID: 28765324
  22. This study demonstrates that simultaneous inhibition of c-Met and Src signaling in MD-MSCs triggers apoptosis and reveals vulnerable pathways that could be exploited to develop NF2 therapies. PMID: 28775147
  23. prolonged treatment of single HGF/c-Met or Hh inhibitor leads to resistance to these single inhibitors, likely because the single c-Met treatment leads to enhanced expression of Shh, and vice versa. Targeting both the HGF/c-Met and Hh pathways simultaneously overcame the resistance to the single-inhibitor treatment and led to a more potent antitumor effect in combination with the chemotherapy treatment. PMID: 28864680
  24. We identified unique and tumor-specific tyrosine phosphorylation rewiring in tumors resistant to treatment with the irreversible third-generation EGFR-inhibitor, osimertinib, or the novel dual-targeting EGFR/Met antibody, JNJ-61186372. PMID: 28830985
  25. TGF-beta negatively controls the HGF/c-MET pathway by regulating of stemness in glioblastoma. PMID: 29238047
  26. The preclinical efficacy and safety data provide a clear rationale for the ongoing clinical studies of Sym015 in patients with MET-amplified tumors. PMID: 28679766
  27. High MET expression is associated with malignant pleural mesothelioma. PMID: 28560410
  28. the results of real-time PCR and western blotting revealed that Huaier extract decreased p65 and c-Met expression and increased IkappaBalpha expression, while paclitaxel increased p65 expression and reduced IkappaBalpha and c-Met expression.The molecular mechanisms may be involved in the inhibition of the NF-kappaB pathway and c-Met expression PMID: 29039556
  29. Data found that the expression of c-Met was significantly increased in human oral squamous cell carcinoma (OSCC) tissues than in normal mucosa adjacent to the tumor, but was not correlated with clinicopathological parameters. Also, further findings indicated the potential role of c-Met in the progression of OSCC. PMID: 29115556
  30. Our data show that S49076 exerts its cytotoxic activity at low doses on MET-dependent cells through MET inhibition, whereas it inhibits growth of MET-independent cells at higher but clinically relevant doses by targeting Aurora B PMID: 28619752
  31. MET expression was shown to be significantly reduced in the superior temporal gyrus cortex of autism spectrum disorders individuals. PMID: 28322981
  32. In SCCHN, immunohistochemical overexpression of c-MET above cut-off levels III and particularly II was associated with inferior survival outcomes and advanced disease PMID: 29103754
  33. Here we present a case series of three such patients who achieved were cMET amplified and showed partial response on Crizotinib PMID: 29199685
  34. c-Met/beta1 integrin complex whose ligand-independent cross-activation and robust affinity for fibronectin drives invasive oncologic processes. PMID: 28973887
  35. tivantinib did not suppress MET signaling, and selective MET inhibitors demonstrated an antiproliferative effect only in MHCC97H, the unique cell line displaying MET gene amplification. HCC tumors with high expression of cell proliferation genes defined a group of patients with poor survival. PMID: 28246274
  36. Studies show that MET mutations have been found in cancer of unknown primary origin (CUP) being clustered to the SEMA and TK domain of the receptor. The biomechanical properties of MET mutants might trigger the hyper-invasive phenotype associated to CUP. [review] PMID: 29037604
  37. Data show that Kruppel like factor 4 (KLF4) was overexpressed in met proto-oncogene protein (c-Met)-overexpressing non-small-cell lung cancer (NSCLC) cells and tissues. PMID: 29624806
  38. SOCS1 attenuates migration and invasion properties of hepatocellular carcinoma cells at least partly via modulation of MET-mediated epithelial-mesenchymal transition, and controls invasive tumor growth. PMID: 29085209
  39. The authors reconfirmed EGFR mutation as a strong predictive marker of Non-Small-Cell Lung Cancer. However, c-MET positivity was not associated with response or progression-free survival, although c-MET overexpression correlated with some clinical characteristics. PMID: 29502124
  40. findings show oncogene E5 is primarily responsible for Met upregulation; E5-induced Met contributes motility of HPV-containing cells; these studies show a new role for E5 in epithelial-stromal interactions, with implications for cancer development PMID: 29609071
  41. EGFR T790M mutation and cMET amplification are main mechanisms leading to EGFR TKI resistance in lung adenocarcinoma. PMID: 29616327
  42. MET activation is associated with drug resistance in chronic myeloid leukemia. PMID: 28418880
  43. High glucose activated Met receptor in HK2 cells independently of HGF, via induction of integrin a5b1 and downstream signaling. This mode of Met activation was associated with tubular cell damage and apoptosis and it may represent a novel pathogenic mechanism and a treatment target in diabetic nephropathy. PMID: 28819999
  44. The purpose of this study was to explore gene copy number (GCN) variation of EGFR, HER2, c-MYC, and MET in patients with primary colorectal cancer. PMID: 28764718
  45. HGF/c-MET pathway mediates VEGFR inhibitor resistance and vascular remodeling in NSCLC. PMID: 28559461
  46. Because c-Met is strongly associated with pathological grade, stage and disease-specific survival, c-Met levels may have potential to predict patient prognosis and to guide clinical diagnosis and treatment of patients with renal cell carcinoma PMID: 28427859
  47. miR-1 is downregulated in ovarian cancer tissues, and may play a tumor suppressive role by inhibiting c-Met expression and its effects on the regulation of cell proliferation, migration and invasion PMID: 28698064
  48. Proto-oncogene proteins c-met (MET) mutations Y1248H and D1246N confer resistance in vitro and in vivo. PMID: 28396313
  49. MET overexpression is found in 23.8% of surgically resected NSCLC. MET amplification prevails in 4.6% and is associated with MET overexpression. Both have no influence on prognosis. PMID: 28838386
  50. study highlights the role of tissue differentiation on pathological response to neoadjuvant chemotherapy in gastric cancer and shows no impact between FOXP3, HER2 and MET expression in terms of tumor regression grading PMID: 29696715

Show More

Hide All

Involvement in disease
Hepatocellular carcinoma (HCC); Renal cell carcinoma papillary (RCCP); Deafness, autosomal recessive, 97 (DFNB97); Osteofibrous dysplasia (OSFD)
Subcellular Location
Membrane; Single-pass type I membrane protein.; [Isoform 3]: Secreted.
Protein Families
Protein kinase superfamily, Tyr protein kinase family
Tissue Specificity
Expressed in normal hepatocytes as well as in epithelial cells lining the stomach, the small and the large intestine. Found also in basal keratinocytes of esophagus and skin. High levels are found in liver, gastrointestinal tract, thyroid and kidney. Also
Database Links

HGNC: 7029

OMIM: 114550

KEGG: hsa:4233

STRING: 9606.ENSP00000317272

UniGene: Hs.132966

Promotions
Reward For Reviews
Free antibody trial
Contact Us

  Email: [email protected]
  Distributors Worldwide

Service

Phage Display Service

Antibody Service

Protein Service

Gene Synthesis Service

Oligo Synthesis Service

Related Articles
TWIK2 channel mediates inflammation, study finds Neutralizing Antibody Stands Out Among Antiviral Therapies SWISS-PROT: When and How to Use It Osteoprotegerin (OPG): What is Its Potential as a Biomarker or Therapeutic Target? Protein Acetylation: An Important Post-translational Modification in Eukaryotic Cells Oncogenes and Cancer Neuronal Markers and Neurodegenerative Diseases GPC3: The Next-Promising Target in Cancer Immunotherapy Claudin 18.2, is a 'Dark Horse' in Anti-tumour Therapy? What Are Histones: Unraveling Their Critical Roles in Disease Pathogenesis Does Antibody-dependent Enhancement Occur in SARS-CoV-2 Infection? Decoding the Biological Complexity of Endometrial Cancer: Essential Insights for Researchers Melanoma, the Most Serious Type of Skin Cancer Multiple Myeloma, One of High-Risk Factors for COVID-19 Information You Must Know about KCNN4 STAT3: a Key Transcriptional Regulator in Cancer Streptococcus pneumoniae, a Primary Cause of Pneumonia The True Face of Tumor Suppressor Gene p53 MUC16 (CA125): a Promising Predictive Marker and Therapeutic Target in Cancer Two Types of Macrophages: M1 and M2 Macrophages EGFR and Its Application in Cancer Therapy An Overview of Cell Death: Necrosis and Apoptosis The Overview of One Category of Important Cell Receptors: Receptor Tyrosine Kinases TNFRSF9: A Potent Immune-Stimulator in Cancer Cross-reactivity of Antibody: Beneficial or Harmful? GCGR: A Regulator of Energy Balance Holds a Potential in Treatment Diabetes NRG1: an Intriguing Therapeutic Target in Diseases Approaches to Determinate Protein Concentration CCR8: a Specific Marker on Tregs Cells, the Next Promising Candidate for Antitumor Drugs! Lysosomal Enzymes and Lysosomal Storage Disorders (LSDs) 2021 Insights on the CAR-T Cell Therapy: the Most Popular Targets for Solid Tumor! Cellular Senescence and Its Markers NKG2D, a Powerful Molecule Involved In CAR-T And Car-NK Cell Therapy How to Properly Reconstitute Lyophilized Proteins? DLL3: A New Molecular Target in Cancer Does LIF Only Play a Role in Leukaemia? How to Choose? Polyclonal, Monoclonal, or Recombinant Antibody? DNA Damage and Repair TFPI: a Natural Anticoagulant Protein, Future Therapies for Hemophilia Chemokine Receptor CCR4: the Key Role of CCR4+Treg Cells in Cancer Immunotherapy DT3C, a Powerful Tool for ADC Drug Internalization In Vitro Proteolysis Targeting Chimera (PROTAC): A "Revolutionary" Technology in Small Molecule Drug Discovery! CLDN6: A "New Favorite" in Targeted Cancer Therapy after CLDN 18.2! CLDN9: Another Key Regulator for Tumors or Hearing Loss from the CLDN Family! DDR1: a Novel Member of the RTKs Family, a Potential Target for Tumor Therapy! RSPO1: The key factor determining "battle of the sexes " is “favored” in the culture of organoids? How to Validate An Antibody？ TPBG/5T4: the Oncofetal Protein, an Appealing Target for ADC or Vaccine Therapeutics in Tumors! CD93, A Rising Star in Anti-Tumor Therapy A Review of A Human NGAL ELISA Kit Intestinal Mucosal Barrier Bodyguard --ALPi GPRC5D: Newly Efficient GPRC5D CAR-T or Bispecific Antibody Therapy to Fight Multiple Myeloma (MM) The Collection of Progress of Anti-GPCR Antibody Drugs Dual Role of TNFRSF14 in Immunology Surface Markers That Help You Identify Lymphocytes ERBB3/HER3: a New Target for Tumor Therapy, a Driver Gene of Multi-Tumors How Do You Get Exosomes? Cell Differentiation Determines the Fate of Cells CD73, What a Powerful Therapy Target in Tumor Immune CAR-T Cell Therapy- An Useful Treatment To Cancer Exploring Biological Landscape of Cervical Cancer: A Comprehensive Overview for Researchers CLDN4: A Potential Prognostic Indicator and Therapeutic Target in Tumors！ What Are the Best Methods for Protein Purification? A Practical Guide CD19-The Most Popular Target with CAR T-Cell Therapy TFR1 (TFRC): a Stimulator of Fe Transport Affects Anemia, Neurodegenerative Disorders and Cancers! Immune Activation: Insights into T Cell Differentiation A Comprehensive Overview of Ovarian Cancer Categories over 10000! --Rare diseases that are no longer SLC7A11: a New Potential Therapeutic Target via Induced Ferroptosis in Tumors! Protein Phosphorylation: The Dynamic Language of Cellular Regulation Tuberculosis--A Resurgent Differentiation of Th17 Cells Tag Antibodies, Your Good Partner in Protein Research ULBP1: a Potent Member of NKG2D Ligands in CAR-T Therapy for Multiple Hematological and Solid Tumors! How to Choose the Loading Control Antibodies? GFRAL: A Promising Metabolic Target for Improving Obesity and Anorexia/Cachexia Microglial Markers: Insights into Microglial Activation and Function Knowledge about Transthyretin How to Inquire and Utilize the Signal Pathway on KEGG Costimulatory/Coinhibitory: Is B7-H3 An Enemy or A Friend? The Overview of Fc Receptors- Classification, Related Signaling Pathways and Application Effects of FSHR on Fertility and Tumors The Overview of Recombinant Antibody DSG2: a Vital Member of Desmosomal Cadherin Family, an Exciting New Target for Cardiomyopathy, Adenovirus, and Tumors! How to Choose the Right Secondary Antibody? Glial Fibrillary Acidic Protein - Astrocyte Specific Marker MYL9: a New Member of Myosin Motors, a Key Driver of Cancer Cell Dynamic Regulation? ZG16B: A New Tumor Biomarker Offers Important Insights for Drug Development in Pancreatic Cancer! New Mechanism, NRP1 Enhances the Ability of SARS-CoV-2 Infection Surface Markers of Mesenchymal Stem Cells Anti-Payload Antibody DXD: A Highly Potent Tool for ADCs Pharmacokinetic (PK) Analysis! Oct4 -- The Gatekeeper of Pluripotency of Embryonic Stem Cells Interleukin 4 receptor (IL-4R/IL-4Ra): a Multifunctional Target of Cytokines, Suggesting Diverse Potential in Asthma, Rhinitis, Viral, and Tumor Research! CEACAM8: a Member of CEA Family, Emerging as a Vital Player in Gynaecological or Gastrointestinal Cancer Research! Biological Activity of Proteins The Overview of Cell Viability Bladder Cancer: Insights into Molecular Biology,Signaling Pathways, and Biomarkers The Metabolic Phenotype of Tumor-Associated Macrophages in the Tumor Microenvironment Stem Cell-What a Miraculous Resource in Human Body IL-6-Do You Really Know That? Growth Hormone - Not Only Promotes Height Increase CEACAM5: A Promising Member of CEACAM Family, A Potential Target for ADC Drug Research! Nanobody, what a Powerful Novel Antibody! What Do You Need to Know Before Researching Human Metapneumovirus? CD147, a New Target of SARS-CoV-2 Invasion DKK1: a Well-Characterized Wnt Inhibitor, a Multifunctional Regulator in Multiple Cancers! One World, One Hope——What Can We Do about AIDS? The Application of IHC in Pathological Diagnosis LPS/TLR4 Signal Transduction Pathway The difference between primary antibody and secondary antibody A Comprehensive Exploration into Amyotrophic Lateral Sclerosis Do you Often Trouble in These Problems of ELISA? The Meaning of Irregular Antibody Screening What Factors Could Affect ELISA Results? A "trembling" Parkinson's Disease Focus on Emerging Therapeutic Targets BCMA Hematopoietic Stem Cell Surface Marker CD20 Monoclonal Antibodies Drugs: There is an Explosion of New mAbs Against CD20! Tumor Necrosis Factor Receptor Superfamily and Apoptosis The Overview of Coagulation The Power and Promise of Stable Cell Lines Understanding of Serum Albumin VSIG4: a Prominent B7 Family Costimulatory Molecule or Complement Receptor in Cancers and Inflammatory Diseases! Monoclonal Antibody Drugs Overview SLC39A6/ZIP6: a Key Member of Zinc Transporters, a Novel Targeting Antigen of ADC! What You Have To Know about Lung Cancer TMEFF2: a Tumor-Specific Methylated Biomarker, a Novel Target in Multiple Cancers Protein Kinases Overview: Definition, Types, Function, Activation Mechanism, etc. Exploring Neurodegeneration: A Comprehensive Guide for Researchers CD44- A Powerful Bridge Between Cells Tools You Need For Fundamental Research How do Th1 and Th2 Cells Differentiate? What Powerful Model Organism Databases Protein Tyrosine Kinases: Anti-tumor Targets to be Explored Urgently TCGA Database- A Good Partner of Researchers GIPR: the Crucial Regulator of Glucose and Lipid Metabolism in Diabetes and Obesity! What a Powerful Artifact of DNA Compression - Histone Epigenetic Histone Modifications Pathway How Does Histone Modification Affect Gene Expression? How to Measure Histone Modification? Histone modification and Cancer Unraveling the Dynamic World of Histone Modifications: Implications in Gene Regulation and Disease Pathogenesis CD48: An Emerging Human Immune Co-stimulatory Molecule, Friend or Foe? Identify Treg Cells. You Can Do This. The Multifunctional Enzyme CD38: A Target for Immunotherapeutic Approaches in Cancer About Thyroid Tumor, This Information You Must Know! What A Paradoxical TNF Signaling Pathway-Based on Different Receptors What Essential Biological Knowledge is Needed for Hepatocellular Carcinoma Research? What Are the Effects of Abnormalities in the ALK Gene These Tumor Databases You Have To Know CD146, A Powerful Tumor Marker ELISA vs. Multiplex Immunoassays: Why ELISA Remains the Gold Standard among Immunoassays GPCR Drugs Discovery Introduction of Hepatocellular Carcinoma Related Signaling Pathways SIGIRR: A Novel Member of the TIR Superfamily Acts as the Anti-Inflammatory 'Brake' to Control Immune Response in Various Diseases! Mesothelin: A Rising Star of Cancer Immunotherapy CD70 (CD27L/TNFSF7): a TNF Receptor Member, a “Star” Target for Clinical Research in Systemic Lupus Erythematosus (SLE), Arthritis, and Tumors! Diabetes: What You Need to Know Before Starting Research? ACE2, The Hottest Target of SARS-CoV-2 Invasion PD-1-- An Important Immune Checkpoint Epitope Tags Overview Tetraspanin CD81: a Key Receptor for Hepatitis C Virus (HCV), an Established Exosome Marker, a Promising Target for Antiviral or Antitumor Research! Does TNF Superfamily Inhibit Cancer or Promote Its Development? An Overview of CD226 and Its Promising Role in Cancer Immunotherapy TROP2, An Important Target for Cancer Research OMA1-A Potential Cancer Therapy Target GLP-1R: An Energy Metabolism Regulator of GPCR Family, an Effective Drug Target for Type 2 Diabetes Therapy! TASIN represents a promising approach for prevention of colorectal cancer Latest Changes in Journal Impact Factor TM4SF1: a Member of the Transmembrane-4-Superfamily (L6), a New Vascular Therapeutic Target? Surface Markers of Natural Killer Cells What Is an Antibody? LY6G6D (LY6-G): A New Member of Lymphocyte Antigen-6 Family Holds Big Opportunities in Bispecific Antibody for CRC Treatment! Exploring the Science of Influenza A Virus: What You Need to Know Mucin-17/MUC17: An Unexpected Target for Tumor Immune Therapy, Notably Gastric Cancer! Applications of recombinant proteins ANGPT2 (Ang-2): the First Bispecific Antibody for Eye Vision Loss Therapy, a Novel Target for Tumor Angiogenesis! How to choose a suitable expression vector? How to express a protein with bioactivity? 11 tips for choosing your right ELISA kit Norwalk Virus Analysis of Factors Influencing ELISA Detection IL-17A: A Major Cytokine of the IL-17 Family, a Key Inflammation Target in Skin Diseases, or Inflammation-Associated Cancers! Protein Tags: A Comprehensive Overview ALPG: a Germ Cell-Associated Alkaline Phosphatase (ALP), a Highly Specific Cell Surface Antigen in Cancers! CUSABIO's Five Expression Systems Serotransferrin/TF: a Major Transferrin in Plasma, a Novel TF-Modified Nanoparticle for Tumor-Targeting Research! Myosin Regulatory Light Chains (MYL12A and MYL12B): the New Functional Ligands for CD69, Potential Targets for Cardiac Disease or Tumors Research? FAP may be a drug target for pancreatic cancer The Overview of Colony Stimulating Factors Do You Really Know Neurons and Glia Cells in Nerve System? Inhibition of ASCT2 combats cancer in vitro and in vivo Get An Overview of His-Tag CD69: a Classical Early Marker of Lymphocyte Activation, a Pivotal Regulator of Hematologic Diseases and Autoimmune Disorders! PD-1/PD-L1, What a Powerful Immune Checkpoint EphA3-A Regulator of Cell Adhesion and Migration Cadherin-17 (CDH17): A Viable Target in Bispecific Antibodies or CAR-T Therapy to Fight Many Gastrointestinal Cancers! Itaconate is a negative regulator of inflammation The Memory thief - Alzheimer's disease The Overview of Growth Factor Tumor Necrosis Factor (TNF) The Overview of Interferon Tumor markers The Oncogene HER2: a New Target for Drug-Resistant Tumors A Group of Promising Proteins - Cell Cycle Markers The Overview of Interleukin The Overview of Organelles The Overview of Autophagy Four Types of ELISA How to Choose an Antibody for Scientific Research? Production of Recombinant Protein The Overview of Phage Display: Protocol, Classification, Application and FAQs Crosstalk Between Autophagy and Apoptosis TTR: an Important Protein of Amyloidosis, Novel Therapies are Upcoming for Rare Diseases ATTR-CM and ATTR-PN! The Overview of Breast Cancer: Related Signaling Pathways, Therapeutic Targets CDCP1: A Key Mediator for Cell Signaling in Cancers, an Emerging Target for Anti-Tumor Drugs! The overview of Wnt signaling pathway The overview of TGF-β signaling pathway PI3K-Akt Signaling Pathway and Cancer Double-Edged Sword: TGF-β Do You Really Know TGF-β Superfamily? CCR9: A Member of the Chemokine Receptor Family, an Emerging Target for Numerous Tumor Researches! Chemokine Receptor CCR6: the Specific Receptor for CCL20, a Potential Target for Drug Research in Inflammatory Diseases and Gastrointestinal Cancer! CEACAM6: a Potent CEA Family Molecule, a New Tumor Marker or Anti-Cancer Target! What Is Tomato Mosaic Virus IL2RA (CD25): A Specific Marker of Tregs Functions as Both Immune Modulators and Targeted Agents in Various Diseases! What Should You Know about Exosomes? Bispecific Antibody Overview: From Definition to Application The Review of Post-translational Modifications IGFL1: A Novel Secretory Protein of IGF-Like Family Presents a High Cancer-Promoting Potential! CXCR4: An Attractive Target of GPCR family Brings Promising New Drugs for Cancer Therapy！ CLDN3: Another Tight Junction Protein or New Drug Target, Interest in CLDN Family is Growing Fast! PROM1 (CD133): A New Cell Surface Marker of Cancer Stem Cells (CSCs), A More Significant Target for Immunotherapy! BDCA2/CLEC4C: a Novel Plasma Cell-Like Dendritic Cell (pDC) Marker and Potent Inhibitor of IFN-I that Blocks SLE Development! ENPP3 (CD203c): An Extracellular Enzyme, a Regulator for Nucleotide and Energy, an Indicator for Allergies, an Effective Target for RCC Therapy! ROR1, an Emerging Target for Tumor Immunotherapy GUCY2C: a Novel Target in Tumor Immunotherapy, Specially in Colorectal Cancer CAR T Therapy! SEMA4D/CD100: As an Important Immunoregulator to Improve Immunotherapy SSTR2: A Prominent Target in SSTR Family, Offers a More Precise Therapy in Neuroendocrine Tumors (NET) CADM1: an Immunoglobulin Superfamily Molecule, a New Tumor Suppressor Gene! Oncostatin M (OSM): A Member of IL-6 Cytokine Family, An Underestimated Player in Future Targeted Therapies? CNR1 (CB1): A Crucial Receptor of Endocannabinoid System Offers Potential Treatments for Tumors and Glycolipid Metabolism Disorders! DSG3: An Emerging Tumor-Associated Adhesion Factor, a Specific Marker for the Clinical Diagnosis of Pemphigus Vulgaris (PV)! MAGEA4: a Member of the Melanoma-Associated Antigen (MAGE) Family, a Popular Target for Tumor-Specific Immune Research! Targeting LRRC15: From tumor microenvironment regulation to fibrotic/infectious disease therapy In Vivo vs. In Vitro: Choosing the Right Experimental Model for Your Research Dipeptidase 3 (DPEP3): an Emerging Member of the DPEP Family, a Potential Therapeutic Target in Male Fertility or Tumor Research! Exploring Protein-Protein Interactions: A Comprehensive Guide to Understanding and Utilizing It IL-6: an Important Participant in the Inflammatory Cascade, One of the Most Functional Cytokines in Various Diseases Research! CT83/KK-LC-1: a Promising Therapeutic Target of CTAs Family, Currently in Clinical Research for Breast, Lung, Gastric Cancers, and Beyond! What Are the Best Antibody Purification Methods for Your Research Needs? What is Myc Tag: Definition, Function, Applications & Comparison with Other Epitope Tags What Is Protein Characterization: Definition, Examples, Methods, and Techniques What is a His Tag? A Guide from Definition to Applications New Power in the Fight Against Cancer: Spotlight on Rising Stars of ADC Drugs at the 2024 ASCO Annual Meeting Nectin-4: a Key Target in the IgSF Family, Boosting Clinical Drug Research in Various Tumors! T Cell Activation - The Switch for T Cell Executive Function Verified vs. Unverified Recombinant Proteins: Making the Right Choice for Your Research How to Choose Monoclonal Antibody Technology? A Definitive Guide Advancements in CDH6-Targeted Drug Research for Cancer Treatment What Bacterial Antigens Are Used in Vaccines? Glycolysis Pathway: The Essential Energy Source for Cells, Even in Low-Oxygen Conditions What Is Compartment Modelling in Pharmacokinetics? ACVR2A and ACVR2B as Key Targets for Muscle Growth, Weight Loss, PHA in Drug Research！ A Comprehensive Guide to Monoclonal Antibody Production How do we dissolve BSA? TIGIT Targeted Immunotherapies Offer New Hope for Cancer Treatment TNFSF15/TL1A: The Rise of the Next Billion-Dollar Target as Pharma Giants Stake Their Claims Antigen Retrieval: Uncovering Antigen Masking to Improve Immunohistochemistry Results How to Choose An Appropriate Isotype Control Antibody? CD79A and CD79B: Key Targets in B Cell Signaling Pathways and Therapeutic Potential CSF2/GM-CSF: A Key Molecule in Immune Regulation and Disease Treatment TNFSF18: Unlocking New Frontiers in Cancer Immunotherapy How AI is Reshaping Biological Research? A Comprehensive Guide to Tools and Practical Strategies IL-6: A Central Factor in Cytokine Storms and a Health Alert for Infections and Diseases How to Choose the Right Recombinant Protein for Your Experimental Model? PVR (CD155): A Key Factor in Tumor Immune Evasion and a Novel Therapeutic Target How the Tumor Microenvironment Fuels Cancer's Deadly Evolution MSTN: A Key Target for Targeted Therapy in Muscle Diseases​ CEACAM1: An Emerging Multifunctional Target for Cancer-Immune Modulation DLL4: A Key Target for Angiogenesis Regulation EDNRA: A Key Target for Disease-Associated Angioplasty, Tumor Invasion, and Metabolic Regulation Pioneering CAR-T Cell Therapy: Advancing Personalized Cancer Treatment How Do CTLA-4 Inhibitors Work? A Complete Guide for Early-Career Researchers CCL17: A Chemokine with Multiple Biological Functions Immune Battlefield's "Scout": Decoding the NCR3 Target PTH1R: Key Therapeutic Target in Bone & Metabolic Health | CUSABIO Colony Stimulating Factor 1 (CSF1): Its Key Role in Diseases and New Progress in Targeted Therapy B7-H6: A Key Ligand of NK Cell Immune Checkpoints Reshaping the Landscape of Tumor Immunotherapy MICB: a key molecule that bridges cellular stress and immune responses MICA: key regulatory molecule for tumor immune surveillance and its therapeutic target potential LYPD3: An Emerging Star in Solid Tumor Therapy TSLP: A Key Target in Allergic and Inflammatory Diseases CUSABIO's Five Expression Systems General Information of Different Tags How to express a protein with bioactivity? How to choose a suitable expression vector? Applications of recombinant proteins Production of Recombinant Protein
Related pathways
MAPK signaling pathway PI3K-Akt signaling pathway Focal adhesion Adherens junction Ras signaling pathway Rap1 signaling pathway Target Therapy
CUSABIO guaranteed quality
icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of email
Email
[email protected]
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2025 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Privacy Policy
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*